These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 19259097)
61. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Vardiman JW Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474 [TBL] [Abstract][Full Text] [Related]
62. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Söderberg KC; Jonsson F; Winqvist O; Hagmar L; Feychting M Eur J Cancer; 2006 Nov; 42(17):3028-33. PubMed ID: 16945522 [TBL] [Abstract][Full Text] [Related]
63. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Sperr WR; Horny HP; Valent P Int Arch Allergy Immunol; 2002 Feb; 127(2):140-2. PubMed ID: 11919425 [TBL] [Abstract][Full Text] [Related]
64. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. Venugopal S; Mascarenhas J; Steensma DP Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878 [TBL] [Abstract][Full Text] [Related]
69. [Role of innate immune signaling and inflammation in the pathogenesis of myeloid malignancies]. Muto T Rinsho Ketsueki; 2023; 64(9):962-969. PubMed ID: 37793872 [TBL] [Abstract][Full Text] [Related]
70. Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Sørensen AL; Hasselbalch HC Leuk Res; 2016 Feb; 41():27-35. PubMed ID: 26718091 [TBL] [Abstract][Full Text] [Related]
71. Expanding the role of the splicing USB1 gene from Poikiloderma with Neutropenia to acquired myeloid neoplasms. Negri G; Crescenzi B; Colombo EA; Fontana L; Barba G; Arcioni F; Gervasini C; Mecucci C; Larizza L Br J Haematol; 2015 Nov; 171(4):557-65. PubMed ID: 26306619 [TBL] [Abstract][Full Text] [Related]
72. Cutaneous extramedullary hemopoiesis in chronic myeloproliferative and myelodysplastic disorders. Haniffa MA; Wilkins BS; Blasdale C; Simpson NB J Am Acad Dermatol; 2006 Aug; 55(2 Suppl):S28-31. PubMed ID: 16843120 [TBL] [Abstract][Full Text] [Related]
73. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926 [TBL] [Abstract][Full Text] [Related]
74. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092 [TBL] [Abstract][Full Text] [Related]